

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

BUSINESS UPDATE

THE EXCLUSIVE DISTRIBUTORSHIP OF ATROPINE EYE DROPS IN GUANGDONG PROVINCE OF CHINA

The board of directors of Jacobson Pharma Corporation Limited (the “**Company**” or “**Jacobson Pharma**”, together with its subsidiaries, the “**Jacobson Pharma Group**”) is pleased to announce that Jacobson Medical (Hong Kong) Limited, a wholly-owned subsidiary of Jacobson Pharma (as the “**Distributor**”), and Aseptic Innovative Medicine Co., Ltd. (as the “**Manufacturer**” or “**AIM**”) entered into an addendum to the Original Exclusive Distributorship Agreement (as defined below) (the “**New Exclusive Distributorship Agreement**”) on 23 January 2019 thereby, among others, the territory thereof has been extended to cover the Guangdong Province of the People’s Republic of China (“**China**”) in relation to the exclusive distribution of the Atropine eye drops (the “**Product**”).

Leveraging on the regional commercial platform of Jacobson Pharma Group, we are well poised and have been active to collaborate strategically with reputable manufacturers globally through in-licensing, technology transfer or representation of finished branded products for expanding our market presence in Asia.

Pursuant to an exclusive distributorship agreement (the “**Original Exclusive Distributorship Agreement**”) entered between the Distributor and AIM on 24 August 2018, the Distributor is appointed as the exclusive distributor of the Product in Hong Kong, Macao and Singapore (the “**Agreed Territories**”) for a period of 3 years. Under the New Exclusive Distributorship Agreement, in addition to the Agreed Territories, AIM has further appointed the Distributor as the exclusive distributor of the Product in the Guangdong Province of China. Since the commencement of the business partnership under the Original Exclusive Distributorship Agreement, over 20,000 boxes of monthly-pack (for 30 days usage) Atropine eye drop

(0.01%) have been prescribed by registered medical practitioners in Hong Kong to over 3,000 designated patients and have been imported into Hong Kong. The Product is currently being imported into Hong Kong on the basis of prescription by registered medical practitioners. We are confident that with our close rapport with medical professionals along with our extensive sales network, Jacobson Pharma Group is well-positioned to exploit the market potential in the Greater Bay Area encompassing Hong Kong, Macao and Guangdong Province.

ABOUT ATROPINE

Atropine eye drops have been widely used by ophthalmologists for pupil dilation and cycloplegic refraction for a long-standing period of time.

Reference is also made on the “**Low-Concentration Atropine for Myopia Progression (LAMP) Study**” conducted from January 2016 to November 2017 at The Chinese University of Hong Kong’s eye centre in Hong Kong. The study’s *Conclusions* are as follows: ***The 0.05%, 0.025%, and 0.01% atropine eye drops reduced myopia progression along a concentration-dependent response. All concentrations were well tolerated without an adverse effect on vision-related quality of life. Of the 3 concentrations used, 0.05% atropine was most effective in controlling SE progression and AL elongation over a period of 1 year.*** Ophthalmology 2018;–:1e12^a 2018 by the American Academy of Ophthalmology 126:1:113-124.

The above only sets out the conclusions of the study. Shareholders and investors should read the full text of the study for information.

ABOUT THE MANUFACTURER

Aseptic Innovative Medicine Co., Ltd., the manufacturer of the Product, was established in 2003 in Taiwan principally engaged in the manufacturing of ophthalmic and pharmaceutical. It is an affiliate of the Ophthalmology and Oral Health Care of Taiwan Biotech Co., Ltd. and became one of the first PIC/S GMP accredited eye preparation manufacturers in Taiwan in 2012. The Manufacturer has expanded into various overseas markets including United States, Singapore, the Philippines, China, Hong Kong, Macao and Ukraine. For more details, please visit the website of Aseptic Innovative Medicine Co., Ltd. (<http://www.aimedicine.com.tw>).

By order of the Board
Jacobson Pharma Corporation Limited
WU Lai King
Company Secretary

Hong Kong, 25 January 2019

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Wong Chi Kei, Ian as independent non-executive Directors.